CTLA4 and neoplasm: Given these data, Ciombor et al. [66] have also proposed a trial for MMR-d patients using PD-1, CTLA-4 blockade, and SCRT to maximize response, and are integrating cCR as an outcome along with rates of pCR, disease-free survival, treatment-related toxicity, sphincter-preservation rates, and tumor regression grade.